若年性特発性関節炎治療の世界市場（2025年～2035年）

若年性特発性関節炎治療の市場規模は、2023年に30億米ドルとなりました。同市場は、予測期間（2025年～2035年）に6.1%のCAGRで拡大し、2035年には58億米ドルに達すると予測されています。JIA治療業界の成長は、若年性特発性関節炎の有病率の高さ、革新的なドラッグデリバリー技術の採用拡大、オーダーメードケアに重点を置いた臨床試験と小児リウマチ研究の統合の高まりによってもたらされます。関節炎財団によると、300万人の子供と若年成人が若年性特発性関節炎に罹患していると推定されており、小児リウマチ性疾患の中で最も有病率の高いタイプです。

集学的治療と早期診断の普及に伴い、市場の動向は変化しています。回復不能な関節損傷を防ぎ、長期的な結果を改善するためには、定期的な介入がますます重要になってきています。小児リウマチ専門医と作業療法士が協力し、それぞれの子どものニーズに合わせた完全なケアプログラムを作成しています。さらに、バイオマーカーや画像技術などの診断方法の進歩が進み、JIAの子どもたちがより良い生活を送れるよう支援されています。ヘルスケア企業は遠隔医療サービスを取り入れ、定期的なフォローアップを可能にし、専門家によるケアへの障害を取り除いています。関節炎財団とそのパートナーは、7月を若年性関節炎（JA）啓発月間と定め、若年性関節炎やその他の小児リウマチ性疾患についての認識を高めています。財団のパートナーには、米国疾病予防管理センター（CDC）、米国国立衛生研究所（NIH）、Childhood Arthritis Rheumatology Research Alliance（CARRA）、Alpha Omicron Pi（AOII）、その他数え切れないほどの団体や個人が含まれます。

若年性特発性関節炎の治療において、生物学的製剤による治療はますます一般的になってきています。インターロイキン阻害薬や腫瘍壊死因子阻害薬を含む先進的な薬剤は、炎症の原因となる特定の免疫経路を標的とすることで受け入れられつつあります。生物学的製剤は、メトトレキサートや非ステロイド性抗炎症薬などの従来の薬剤よりも、若年患者における長期的な関節損傷のリスクを軽減するために、より個別化された治療を提供します。バイオシミラーの研究が進むにつれ、費用対効果や治療へのアクセスも向上しています。小児を対象とした生物学的製剤の受容が進んでいます。中等度から重度の場合、症状管理を改善するために生物学的製剤を勧める医師が増えています。介護者の間で、これらの医薬品の有効性に対する認識が高まっていることが、その受容性に寄与しています。一部の地域では規制当局の認可が下り、治療アプローチへの組み入れが加速しています。この動向は、自己免疫疾患の管理における精密医療への幅広いシフトを反映しています。

当レポートでは、世界の若年性特発性関節炎治市場について調査し、市場の概要とともに、タイプ別、投与経路別、薬剤クラス別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 報告書のサマリー

第2章 市場概要と洞察

第3章 市場の決定要因

• 市場促進要因
• 市場の問題点と課題
• 市場機会

第4章 競合情勢

• 競合ダッシュボード- 若年性特発性関節炎治療市場の収益とメーカー別シェア
• 主要企業分析
  • Bristol Myers Squibb Co. (BMS)
  • Eli Lilly and Co.
  • Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
• 市場参入企業による主な成功戦略
  • 合併と買収
  • 製品発売
  • パートナーシップとコラボレーション

第5章 世界の若年性特発性関節炎治療市場の売上分析（100万米ドル）、タイプ別

• 全身性若年性関節リウマチ（スチル病）
• 少関節型若年性関節炎
• 多関節型若年性関節リウマチ（リウマチ因子陽性および陰性）
• 乾癬性関節炎
• 付着部炎関連関節炎
• 未分化関節炎

第6章 世界の若年性特発性関節炎治療市場の売上分析（100万米ドル）、投与経路別

• 経口
• 注射
• 局所

第7章 世界の若年性特発性関節炎治療市場の売上分析（100万米ドル）、薬剤クラス別

• 非ステロイド性抗炎症薬（NSAID）
• 疾患修飾性抗リウマチ薬（DMARD）
• コルチコステロイド
• その他の医薬品（生物学的製剤）

第8章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第9章 企業プロファイル

• AbbVie Inc.
• Amgen Inc.
• Biogen Inc.
• Bio-Thera Solutions, Ltd.
• Bristol Myers Squibb Co.（BMS）
• CELLTRION INC.
• Chugai Pharmaceutical Co., Ltd.
• Cumberland Pharmaceuticals Inc.
• Eli Lilly and Co.
• Fresenius SE & Co. KGaA
• Genentech, Inc.
• Hoffmann-La Roche AG
• Johnson & Johnson Services, Inc.
• Laboratorios Gebro Pharma, SA
• Mylan N.V.
• Novartis International AG
• Ono Pharmaceutical Co., Ltd.
• Organon & Co.
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Rosemont Pharmaceuticals Ltd.
• Samsung Bioepis Co., Ltd.
• Sanofi S.A.
• Shanghai Henlius Biotech, Inc.
• Swedish Orphan Biovitrum AB（"Sobi"）
• Teva Pharmaceutical Industries Ltd.
• Therakind Ltd.

LIST OF TABLES

• 1. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024-2035 ($ Million)
• 2. Global Systemic JIA (Still's Disease) Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 3. Global Oligoarticular JIA Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 4. Global Polyarticular JIA (Rheumatoid Factor Positive and Negative) Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 5. Global Psoriatic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 6. Global Enthesitis-Related Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 7. Global Undifferentiated Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 8. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024-2035 ($ Million)
• 9. Global Oral Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 10. Global Injectable Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 11. Global Topical Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 12. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024-2035 ($ Million)
• 13. Global Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) For Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 14. Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) For Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 15. Global Corticosteroids for Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 16. Global Other Juvenile Idiopathic Arthritis Treatment Drug Class Market Research and Analysis by Region, 2024-2035 ($ Million)
• 17. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 18. North American Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Country, 2024-2035 ($ Million)
• 19. North American Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024-2035 ($ Million)
• 20. North American Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024-2035 ($ Million)
• 21. North American Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024-2035 ($ Million)
• 22. European Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Country, 2024-2035 ($ Million)
• 23. European Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024-2035 ($ Million)
• 24. European Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024-2035 ($ Million)
• 25. European Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024-2035 ($ Million)
• 26. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Country, 2024-2035 ($ Million)
• 27. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024-2035 ($ Million)
• 28. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024-2035 ($ Million)
• 29. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024-2035 ($ Million)
• 30. Rest Of the World Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Region, 2024-2035 ($ Million)
• 31. Rest Of the World Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024-2035 ($ Million)
• 32. Rest Of the World Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024-2035 ($ Million)
• 33. Rest Of the World Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024-2035 ($ Million)

LIST OF FIGURES

• 1. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Type, 2024 Vs 2035 (%)
• 2. Global Systemic JIA (Still's Disease) Treatment Market Share by Region, 2024 Vs 2035 (%)
• 3. Global Oligoarticular JIA Treatment Market Share by Region, 2024 Vs 2035 (%)
• 4. Global Polyarticular JIA (Rheumatoid Factor Positive and Negative) Treatment Market Share by Region, 2024 Vs 2035 (%)
• 5. Global Psoriatic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 6. Global Enthesitis-Related Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 7. Global Undifferentiated Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 8. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Route of Administration, 2024 Vs 2035 (%)
• 9. Global Oral Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 10. Global Injectable Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 11. Global Topical Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 12. Global Juvenile Idiopathic Arthritis Treatment Market Research and Analysis by Drug Class, 2024 Vs 2035 (%)
• 13. Global Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) For Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 14. Global Disease-Modifying Anti-Rheumatic Drugs (DMARDs) For Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 15. Global Corticosteroids for Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 16. Global Other Juvenile Idiopathic Arthritis Treatment Drug Class Market Share by Region, 2024 Vs 2035 (%)
• 17. Global Juvenile Idiopathic Arthritis Treatment Market Share by Region, 2024 Vs 2035 (%)
• 18. US Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 19. Canada Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 20. UK Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 21. France Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 22. Germany Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 23. Italy Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 24. Spain Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 25. Rest Of Europe Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 26. India Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 27. China Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 28. Japan Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 29. South Korea Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 30. Rest Of Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 31. Latin America Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)
• 32. Middle East and Africa Juvenile Idiopathic Arthritis Treatment Market Size, 2024-2035 ($ Million)

Juvenile Idiopathic Arthritis Treatment Market Size, Share & Trends Analysis Report by Type (Systemic JIA (Still's Disease), Oligoarticular JIA, Polyarticular JIA (Rheumatoid Factor Positive and Negative), Psoriatic Arthritis, Enthesitis-Related Arthritis and Undifferentiated Arthritis), by Route of Administration (Oral, Injectable, and Topical), and by Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Corticosteroids and Other Medications) Forecast Period (2025-2035)

Industry Overview

Juvenile idiopathic arthritis treatment market was valued at $3.0 billion in 2023 and is projected to reach $5.8 billion by 2035, growing at a CAGR of 6.1% during the forecast period (2025-2035). The JIA therapeutic industry growth is driven by the high prevalence of juvenile idiopathic arthritis, the growing adoption of innovative drug delivery technologies, and the growing integration of clinical trials with pediatric rheumatology research with a rising emphasis on customized care. According to the Arthritis Foundation, 3 million children and young adults are estimated to be affected by Juvenile idiopathic arthritis, the most prevalent type of pediatric rheumatic disease.

Market Dynamics

Increasing Focus on Early Diagnosis and Multidisciplinary Care

The market trend is changing as multidisciplinary care and early diagnosis growing more widely used. Regular intervention has grown increasingly vital to prevent irreparable joint damage and improve overall long-term results. Pediatric rheumatologists and occupational therapists collaborate to create complete care programs that are tailored to each child's needs. Additionally, increasing advancements in diagnostic methods such as biomarkers and imaging technology are being made to help children with JIA live better lives. Healthcare companies incorporate telemedicine services to enable regular follow-ups and remove obstacles to expert care. The Arthritis Foundation and its partners have designated July as Juvenile Arthritis (JA) Awareness Month to raise awareness about juvenile arthritis and other childhood rheumatic diseases. Foundation partners include the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Childhood Arthritis Rheumatology Research Alliance (CARRA), Alpha Omicron Pi (AOII), and countless other organizations and individuals.

Growing Expansion of Biologic Therapies

Biologic therapies are increasingly common for the treatment of juvenile idiopathic arthritis. Advanced medications including interleukin and tumor necrosis factor inhibitors are gaining acceptance to target particular immune pathways responsible for inflammation. Biologics offer more individualized care than conventional medications such as methotrexate or NSAIDs, to reduce the risk of long-term joint injury in young patients. Growing research in biosimilars results in increasing cost-effectiveness and access to these treatments. The increasing acceptance of biological drugs intended for use in children. For moderate to severe instances, doctors are increasingly recommending biologics to improve symptom management. The growing awareness of these medicines' efficacy among caregivers is contributing to their acceptability. Regulatory authorization in certain places has accelerated their integration into therapeutic approaches. This trend reflects the broader shift toward precision medicine in the management of autoimmune diseases.

Market Segmentation

• Based on the type, the market is segmented into systemic JIA (still's disease), oligoarticular JIA, polyarticular JIA (rheumatoid factor positive and negative), psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis.
• Based on the route of administration, the market is segmented into oral, injectable, and topical.
• Based on the drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, and other medications (biologic agents).

Know More About JIA Types and Symptoms

Systemic arthritis typically has symptoms such as spiking fever, rash, and arthritis, with about a quarter of children potentially developing severe destructive disease. Oligoarthritis involves up to four joints within the first six months and can either remain persistent (affecting no more than four joints) or become extended (affecting more than four joints after six months); it is often associated with uveitis. Rheumatoid-factor positive (RF+) polyarthritis affects five or more joints within the first six months and is more likely to lead to destructive joint disease, with a possible association with uveitis. Similarly, rheumatoid-factor negative (RF-) polyarthritis also involves five or more joints within the first six months and may be linked to uveitis. Enthesitis-related arthritis and psoriatic arthritis may both be associated with uveitis. Lastly, undifferentiated arthritis refers to cases lasting more than six weeks that either do not meet the criteria for any specific category or fulfill criteria for multiple categories.

Psoriatic Arthritis Segment to Lead the Market with the Largest Share

Growing advancements in psoriatic arthritis treatments with innovative biologics and disease-modifying antirheumatic drugs, that are crucial for symptom control and improving patient outcomes, are the main growth drivers. To continue to expand the availability of effective pharmaceuticals globally, more funds are being allocated to research and development in response to the growing demand for specific therapies to treat psoriatic arthritis in young people. For instance, in May 2024, Boehringer Ingelheim announced that the US FDA has authorized the citrate-free, high-concentration version of Cyltezo(R) (adalimumab-adbm) for the treatment of many chronic inflammatory conditions. Cyltezo is used to treat psoriatic arthritis (PsA) in adults and moderate to severe polyarticular JIA in children aged 2 and up. Methotrexate and CYLTEZO can be taken together or separately.

Injectable: A Key Segment in Market Growth

The factors supporting segment growth include the increasing innovation in treatments involving injections, by reducing inflammation and improving joint function, such therapies offer focused relief. Injectable medications are growing increasingly common among doctors owing to their rapid action and sustained efficacy. Injectable biologic drugs play a crucial role in the management of severe JIA. For instance, in June 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has approved Kevzara(R) (sarilumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA), a type of arthritis that affects numerous joints at once. KEVZARA(R) is a prescription injectable medication that blocks the interleukin-6 (IL-6) receptor. KEVZARA is used to treat active polyarticular juvenile idiopathic arthritis (pJIA) and polymyalgia rheumatica (PMR).

Regional Outlook

The global juvenile idiopathic arthritis treatment market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America)

Growing Investment in Research and Development in Europe

The market for JIA treatments in Europe is expected to rise significantly owing to developments in biologic therapy with a rising incidence of juvenile idiopathic arthritis, the launch of biosimilars, and higher R&D spending. According to the Journal of Health Economics and Outcomes Research (JHEOR), in December 2023, JIA is the most frequent chronic rheumatic disease in children, with an annual incidence of 2 to 20 per 100 000 children and a prevalence in Europe of 16.9 to 167 per 100 000. Pharmaceutical companies are constantly funding research and development to find more effective treatments for JIA. The growth of collaborations between research centers and medical institutions is another element driving progress.

North America Region Dominates the Market with Major Share

North America holds a significant share owing to the presence of juvenile idiopathic arthritis treatment offering companies such as AbbVie Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Pfizer Inc., and others. According to the Centers for Disease Control and Prevention (CDC) (in July 2023), the prevalence of JIA is most common between the ages of 12 and 17 in 2017-2021. In the US 220,000 children and adolescents in the US were diagnosed with arthritis. Early diagnosis, increased treatment choices owing to increased awareness, and a rise in pediatric JIA patients all contributed to the market's expansion. The major companies provide a high-concentration, citrate-free formulation for the treatment of juvenile idiopathic arthritis. For instance, in August 2024, Celltrion USA, Inc. announced that FDA-approved biosimilar adalimumab-aaty. Adalimumab-Aaty is a citrate-free biosimilar of Humira(R) (adalimumab) that is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and Hidradenitis Suppurativa. It has a high concentration (100 mg/mL).

Market Players Outlook

The major companies operating in the global juvenile idiopathic arthritis treatment market include Bristol Myers Squibb Co. (BMS), Eli Lilly and Co., Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In February 2024, Alvotech and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. announced that the US (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an equivalent biosimilar to Humira, SIMLANDI (adalimumab-ryvk) injection has been approved by the US (FDA) to treat adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.
• In January 2023, Samsung Bioepis Co., Ltd. announced that HADLIMATM (also called SB5), a citrate-free, high concentration (40 mg/0.4 ML) biosimilar formulation referencing HUMIRA(R) (adalimumab), has been approved by Health Canada. Adult Crohn's disease, ulcerative colitis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis (RA), adult and adolescent hidradenitis suppurativa, plaque psoriasis, and adult and pediatric uveitis are among the conditions for which HADILMA is prescribed.

The Report Covers:

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global juvenile idiopathic arthritis treatment market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration | Drug Class ($ Million)
• Juvenile Idiopathic Arthritis Treatment Market Sales Performance of Top Countries
• 1.1. Research Methodology
• Primary Research Approach
• Secondary Research Approach
• 1.2. Market Snapshot

2. Market Overview and Insights

• 2.1. Scope of the Study
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Juvenile Idiopathic Arthritis Treatment Industry Trends
  • 2.2.2. Market Recommendations
• 2.3. Porter's Five Forces Analysis for the Juvenile Idiopathic Arthritis Treatment Market
  • 2.3.1. Competitive Rivalry
  • 2.3.2. Threat of New Entrants
  • 2.3.3. Bargaining Power of Suppliers
  • 2.3.4. Bargaining Power of Buyers
  • 2.3.5. Threat of Substitutes

3. Market Determinants

• 3.1. Market Drivers
  • 3.1.1. Drivers For Global Juvenile Idiopathic Arthritis Treatment Market: Impact Analysis
• 3.2. Market Pain Points and Challenges
  • 3.2.1. Restraints For Global Juvenile Idiopathic Arthritis Treatment Market: Impact Analysis
• 3.3. Market Opportunities

4. Competitive Landscape

• 4.1. Competitive Dashboard - Juvenile Idiopathic Arthritis Treatment Market Revenue and Share by Manufacturers
• 4.2. Key Company Analysis
  • 4.2.1. Bristol Myers Squibb Co. (BMS)
    • 4.2.1.1. Overview
    • 4.2.1.2. Product Portfolio
    • 4.2.1.3. Financial Analysis (Subject to Data Availability)
    • 4.2.1.4. SWOT Analysis
    • 4.2.1.5. Business Strategy
  • 4.2.2. Eli Lilly and Co.
    • 4.2.2.1. Overview
    • 4.2.2.2. Product Portfolio
    • 4.2.2.3. Financial Analysis (Subject to Data Availability)
    • 4.2.2.4. SWOT Analysis
    • 4.2.2.5. Business Strategy
  • 4.2.3. Hoffmann-La Roche AG
    • 4.2.3.1. Overview
    • 4.2.3.2. Product Portfolio
    • 4.2.3.3. Financial Analysis (Subject to Data Availability)
    • 4.2.3.4. SWOT Analysis
    • 4.2.3.5. Business Strategy
  • 4.2.4. Johnson & Johnson Services, Inc.
    • 4.2.4.1. Overview
    • 4.2.4.2. Product Portfolio
    • 4.2.4.3. Financial Analysis (Subject to Data Availability)
    • 4.2.4.4. SWOT Analysis
    • 4.2.4.5. Business Strategy
  • 4.2.5. Pfizer Inc.
    • 4.2.5.1. Overview
    • 4.2.5.2. Product Portfolio
    • 4.2.5.3. Financial Analysis (Subject to Data Availability)
    • 4.2.5.4. SWOT Analysis
    • 4.2.5.5. Business Strategy
• 4.3. Top Winning Strategies by Market Players
  • 4.3.1. Merger and Acquisition
  • 4.3.2. Product Launch
  • 4.3.3. Partnership And Collaboration

5. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Type ($ Million)

• 5.1. Systemic JIA (Still's Disease)
• 5.2. Oligoarticular JIA
• 5.3. Polyarticular JIA (Rheumatoid Factor Positive and Negative)
• 5.4. Psoriatic Arthritis
• 5.5. Enthesitis-Related Arthritis
• 5.6. Undifferentiated Arthritis

6. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Route of Administration ($ Million)

• 6.1. Oral
• 6.2. Injectable
• 6.3. Topical

7. Global Juvenile Idiopathic Arthritis Treatment Market Sales Analysis by Drug Class ($ Million)

• 7.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 7.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• 7.3. Corticosteroids
• 7.4. Other Medications (Biologic Agents)

8. Regional Analysis

• 8.1. North American Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for North America
  • 8.1.1. United States
  • 8.1.2. Canada
• 8.2. European Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for Europe
  • 8.2.1. UK
  • 8.2.2. Germany
  • 8.2.3. Italy
  • 8.2.4. Spain
  • 8.2.5. France
  • 8.2.6. Russia
  • 8.2.7. Rest of Europe
• 8.3. Asia-Pacific Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for Asia-Pacific
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
  • 8.3.4. India
  • 8.3.5. Australia & New Zealand
  • 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
  • 8.3.7. Rest of Asia-Pacific
• 8.4. Rest of the World Juvenile Idiopathic Arthritis Treatment Market Sales Analysis - Type| Route of Administration| Drug Class | Country ($ Million)
• Macroeconomic Factors for the Rest of the World
  • 8.4.1. Latin America
  • 8.4.2. Middle East and Africa

9. Company Profiles

• 9.1. AbbVie Inc.
  • 9.1.1. Quick Facts
  • 9.1.2. Company Overview
  • 9.1.3. Product Portfolio
  • 9.1.4. Business Strategies
• 9.2. Amgen Inc.
  • 9.2.1. Quick Facts
  • 9.2.2. Company Overview
  • 9.2.3. Product Portfolio
  • 9.2.4. Business Strategies
• 9.3. Biogen Inc.
  • 9.3.1. Quick Facts
  • 9.3.2. Company Overview
  • 9.3.3. Product Portfolio
  • 9.3.4. Business Strategies
• 9.4. Bio-Thera Solutions, Ltd.
  • 9.4.1. Quick Facts
  • 9.4.2. Company Overview
  • 9.4.3. Product Portfolio
  • 9.4.4. Business Strategies
• 9.5. Bristol Myers Squibb Co. (BMS)
  • 9.5.1. Quick Facts
  • 9.5.2. Company Overview
  • 9.5.3. Product Portfolio
  • 9.5.4. Business Strategies
• 9.6. CELLTRION INC.
  • 9.6.1. Quick Facts
  • 9.6.2. Company Overview
  • 9.6.3. Product Portfolio
  • 9.6.4. Business Strategies
• 9.7. Chugai Pharmaceutical Co., Ltd.
  • 9.7.1. Quick Facts
  • 9.7.2. Company Overview
  • 9.7.3. Product Portfolio
  • 9.7.4. Business Strategies
• 9.8. Cumberland Pharmaceuticals Inc.
  • 9.8.1. Quick Facts
  • 9.8.2. Company Overview
  • 9.8.3. Product Portfolio
  • 9.8.4. Business Strategies
• 9.9. Eli Lilly and Co.
  • 9.9.1. Quick Facts
  • 9.9.2. Company Overview
  • 9.9.3. Product Portfolio
  • 9.9.4. Business Strategies
• 9.10. Fresenius SE & Co. KGaA
  • 9.10.1. Quick Facts
  • 9.10.2. Company Overview
  • 9.10.3. Product Portfolio
  • 9.10.4. Business Strategies
• 9.11. Genentech, Inc.
  • 9.11.1. Quick Facts
  • 9.11.2. Company Overview
  • 9.11.3. Product Portfolio
  • 9.11.4. Business Strategies
• 9.12. Hoffmann-La Roche AG
  • 9.12.1. Quick Facts
  • 9.12.2. Company Overview
  • 9.12.3. Product Portfolio
  • 9.12.4. Business Strategies
• 9.13. Johnson & Johnson Services, Inc.
  • 9.13.1. Quick Facts
  • 9.13.2. Company Overview
  • 9.13.3. Product Portfolio
  • 9.13.4. Business Strategies
• 9.14. Laboratorios Gebro Pharma, SA
  • 9.14.1. Quick Facts
  • 9.14.2. Company Overview
  • 9.14.3. Product Portfolio
  • 9.14.4. Business Strategies
• 9.15. Mylan N.V.
  • 9.15.1. Quick Facts
  • 9.15.2. Company Overview
  • 9.15.3. Product Portfolio
  • 9.15.4. Business Strategies
• 9.16. Novartis International AG
  • 9.16.1. Quick Facts
  • 9.16.2. Company Overview
  • 9.16.3. Product Portfolio
  • 9.16.4. Business Strategies
• 9.17. Ono Pharmaceutical Co., Ltd.
  • 9.17.1. Quick Facts
  • 9.17.2. Company Overview
  • 9.17.3. Product Portfolio
  • 9.17.4. Business Strategies
• 9.18. Organon & Co.
  • 9.18.1. Quick Facts
  • 9.18.2. Company Overview
  • 9.18.3. Product Portfolio
  • 9.18.4. Business Strategies
• 9.19. Pfizer Inc.
  • 9.19.1. Quick Facts
  • 9.19.2. Company Overview
  • 9.19.3. Product Portfolio
  • 9.19.4. Business Strategies
• 9.20. Regeneron Pharmaceuticals, Inc.
  • 9.20.1. Quick Facts
  • 9.20.2. Company Overview
  • 9.20.3. Product Portfolio
  • 9.20.4. Business Strategies
• 9.21. Rosemont Pharmaceuticals Ltd.
  • 9.21.1. Quick Facts
  • 9.21.2. Company Overview
  • 9.21.3. Product Portfolio
  • 9.21.4. Business Strategies
• 9.22. Samsung Bioepis Co., Ltd.
  • 9.22.1. Quick Facts
  • 9.22.2. Company Overview
  • 9.22.3. Product Portfolio
  • 9.22.4. Business Strategies
• 9.23. Sanofi S.A.
  • 9.23.1. Quick Facts
  • 9.23.2. Company Overview
  • 9.23.3. Product Portfolio
  • 9.23.4. Business Strategies
• 9.24. Shanghai Henlius Biotech, Inc.
  • 9.24.1. Quick Facts
  • 9.24.2. Company Overview
  • 9.24.3. Product Portfolio
  • 9.24.4. Business Strategies
• 9.25. Swedish Orphan Biovitrum AB ("Sobi")
  • 9.25.1. Quick Facts
  • 9.25.2. Company Overview
  • 9.25.3. Product Portfolio
  • 9.25.4. Business Strategies
• 9.26. Teva Pharmaceutical Industries Ltd.
  • 9.26.1. Quick Facts
  • 9.26.2. Company Overview
  • 9.26.3. Product Portfolio
  • 9.26.4. Business Strategies
• 9.27. Therakind Ltd.